SCHEMBL10328613

SCHEMBL10328613

CC(C)Oc1coc(C(=O)O)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 5/20 0.36
IRAK4 Q9NWZ3 2/20 0.35
BRPF1 P55201 1/20 0.35
PTGER4 P35408 1/20 0.35
PTGS1 P23219 2/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 1/20 0.35
GPR35 Q9HC97 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
SLC6A2 P23975 1/20 0.35
MAPK1 P28482 1/20 0.35
STAT1 P42224 1/20 0.35
CASP3 P42574 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3217997 0.84 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2KDM4EMAPTLMNA
SCHEMBL31203341 0.81 KDM4E (0.42) ALDH1A1SMN1; SMN2KMT2AKDM4EPTGS1
SCHEMBL10328645 0.80 LMNA (0.43) ALDH1A1SMN1; SMN2PTGER4MAPTLMNA
SCHEMBL14818675 0.80 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2KMT2AKDM4EPTGER4
SCHEMBL6900481 0.76 MEN1 (0.42) KMT2APTGER4MEN1GPR35TDP1
SCHEMBL10328605 0.74 MEN1 (0.48) ALDH1A1KMT2AMEN1TDP1ELANE
SCHEMBL10328545 0.74 FABP3 (0.41) ALDH1A1KMT2AKDM4EPTGER4PTGS1
SCHEMBL10328638 0.73 PTGER4 (0.38) SMN1; SMN2KMT2APTGER4MEN1LMNA
SCHEMBL10328547 0.73 NPC1 (0.51) ALDH1A1SMN1; SMN2KMT2AKDM4EPTGER4
SCHEMBL10328548 0.73 MEN1 (0.50) ALDH1A1KMT2AMEN1TDP1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748483-B2 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome SANOFI (FR) 2014-06-10 US disclosed
US-8748483-B2 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome SANOFI (FR) 2014-06-10 US disclosed
EP-2120923-B1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI SA (FR) 2012-07-18 EP disclosed
US-20100144862-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2010-06-10 US disclosed
US-20100144862-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2010-06-10 US disclosed
WO-2008086949-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144862-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME PC, PCK1, PDK4 ALDH1A1 951/4885SMN1; SMN2 4489/4885KMT2A 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.